MedinCell Past Earnings Performance
Past criteria checks 0/6
MedinCell's earnings have been declining at an average annual rate of -13.9%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 11.9% per year.
Key information
-13.9%
Earnings growth rate
-3.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 11.9% |
| Return on equity | n/a |
| Net Margin | -234.4% |
| Next Earnings Update | 06 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How MedinCell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 14 | -32 | 10 | 28 |
| 31 Dec 22 | 13 | -29 | 9 | 28 |
| 30 Sep 22 | 8 | -27 | 9 | 27 |
| 30 Jun 22 | 6 | -26 | 9 | 25 |
| 31 Mar 22 | 8 | -25 | 8 | 24 |
| 31 Dec 21 | 9 | -22 | 8 | 23 |
| 30 Sep 21 | 9 | -20 | 8 | 23 |
| 30 Jun 21 | 9 | -19 | 8 | 21 |
| 31 Mar 21 | 8 | -19 | 7 | 20 |
| 31 Dec 20 | 7 | -22 | 7 | 18 |
| 30 Sep 20 | 5 | -26 | 8 | 17 |
| 30 Jun 20 | 6 | -25 | 8 | 17 |
| 31 Mar 20 | 6 | -24 | 8 | 17 |
| 31 Dec 19 | 6 | -21 | 8 | 16 |
| 30 Sep 19 | 6 | -19 | 8 | 15 |
| 30 Jun 19 | 5 | -19 | 8 | 13 |
| 31 Mar 19 | 4 | -20 | 8 | 12 |
| 31 Dec 18 | 6 | -17 | 7 | 11 |
| 30 Sep 18 | 7 | -15 | 7 | 10 |
| 30 Jun 18 | 8 | -12 | 6 | 9 |
| 31 Mar 18 | 8 | -10 | 6 | 9 |
| 31 Mar 17 | 10 | -4 | 4 | 8 |
| 31 Mar 16 | 9 | 1 | 3 | 6 |
Quality Earnings: MEDCLP is currently unprofitable.
Growing Profit Margin: MEDCLP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MEDCLP is unprofitable, and losses have increased over the past 5 years at a rate of 13.9% per year.
Accelerating Growth: Unable to compare MEDCLP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MEDCLP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-41.9%).
Return on Equity
High ROE: MEDCLP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.